Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | CCR3 | P51677 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 8/20 | 0.46 |
| ▸ | HTR2B | P41595 | 7/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411155 | 0.87 | HRH1 (0.51) | HRH1CCR3HTR2CHTR2BSLC6A4 | |
| SCHEMBL2924499 | 0.86 | HTR2C (0.56) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL4995893 | 0.85 | HTR2C (0.55) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4969392 | 0.81 | HRH1 (0.56) | HRH1CCR3HTR2CHTR2BSLC6A4 | |
| SCHEMBL5417002 | 0.81 | CCR3 (0.45) | HRH1CCR3SLC6A4 | |
| SCHEMBL5414677 | 0.80 | CCR3 (0.54) | HRH1CCR3 | |
| SCHEMBL18768218 | 0.79 | RORC (0.46) | HRH1CCR3HTR2CHTR2BHTR2A | |
| SCHEMBL6567690 | 0.78 | CCR3 (0.63) | HRH1CCR3 | |
| SCHEMBL5414867 | 0.77 | UTS2R (0.44) | HRH1CCR3HTR2CHTR2BSLC6A4 | |
| SCHEMBL15219288 | 0.76 | HRH1 (0.50) | HRH1CCR3HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482363-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| EP-1487817-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-06-04 | — | — | EP | disclosed |
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | disclosed |
| EP-1404667-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1604982-A1 | INTERMEDIATES FOR THE PREPARATION OF PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050182094-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | disclosed |
| EP-1487817-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078421-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182094-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | HRH1 42/4885CCR3 1/4885HTR2C 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.